0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2006;295(7):723. doi:10.1001/jama.295.7.723.
Text Size: A A A
Published online

RIMONABANT, WEIGHT, AND CARDIOMETABOLIC RISK

Prior investigations suggested that treatment with the selective cannabinoid-1 receptor blocker rimonabant reduces body weight and improves several cardiometabolic risk factors. Pi-Sunyer and colleaguesArticle report results of a randomized trial comparing the efficacy and safety of rimonabant (5 mg and 20 mg) with placebo, plus diet and exercise, on 1- and 2-year changes in body weight and cardiometabolic risk factors in overweight or obese patients. The authors found that rimonabant was generally well tolerated and that the 20-mg dose was more effective than placebo in reducing weight, waist circumference, and triglyceride levels and increasing high-density lipoprotein cholesterol during the first year. In year 2, patients who continued taking 20 mg of rimonabant maintained their weight loss, whereas patients who were rerandomized to placebo regained weight. In an editorial, Simons-Morton and colleaguesArticle discuss the implications of participants' nonadherence and loss to follow-up for interpretation of the study results.

BODY WEIGHT AND MORTALITY IN CHINA

Most studies assessing the effects of underweight and obesity on mortality have been conducted in Western populations and little is known about the associations in Asian populations. Gu and colleagues examined the relationship between body mass index (BMI) and mortality in a nationally representative sample of Chinese men and women 40 years and older. After adjusting for a number of demographic factors, the authors found a U-shaped association between BMI and all-cause mortality. Men with a BMI of 24.0 to 24.9 and women with a BMI of 25.0 to 26.9 had the lowest risk of all-cause mortality.

SOCIOECONOMIC STATUS, EXERCISE, AND MORTALITY

Lower socioeconomic status (SES) has been associated with increased all-cause and cardiovascular mortality. Shishehbor and colleagues hypothesized that functional capacity and heart rate recovery are associated with lower SES. They tested this hypothesis and assessed the contribution of these measures to the SES-mortality relationship in a prospective cohort study of patients referred for exercise stress testing. The authors found that impaired functional capacity and abnormal heart rate recovery were strongly and independently associated with lower SES and accounted for a large portion of the correlation between SES and mortality.

MORPHINE AND TETRACAINE FOR NEONATAL PAIN

In a randomized trial of ventilated neonates having central line placement, Taddio and colleagues assessed the effectiveness and safety of topical tetracaine, intravenous morphine, and the combination compared with no treatment and relative to each other. The authors found that compared with no treatment or tetracaine alone, morphine and tetracaine plus morphine were associated with lower pain scores. Morphine caused respiratory depression and tetracaine caused erythema.

PROGNOSTIC INDEX OF 4-YEAR MORTALITY IN OLDER ADULTS

Prognostic data are useful to inform decision making by patients and clinicians. Using data from a population-based study of community-dwelling US adults 50 years and older, Lee and colleagues developed and validated a prognostic index for 4-year mortality based on simple-to-obtain patient-reported variables.

A PIECE OF MY MIND

“Chris . . . was wide wake when I told him there was nothing more that I, as his physician, could do for him other than make his last days more peaceful and dignified. ‘I understand,’ he said.” From “Errands.”

MEDICAL NEWS & PERSPECTIVES

Clinical trial results indicate that two novel oral anticoagulants may be promising alternatives to current drugs used to treat and prevent thromboembolic events following orthopedic surgery.

CLINICIAN'S CORNER

Evolving indications for the implantable cardioverter-defibrillator (ICD) and advances in technology are reviewed.

THE METABOLIC SYNDROME AND CHD RISK

The metabolic syndrome was found to be inferior to the Framingham Risk Score in predicting coronary heart disease (CHD) in middle-aged men in a study reported in the Archives of Internal Medicine. Kohli and Greenland discuss the utilities of individual and global risk-factor assessments in predicting or preventing future cases of CHD.

POLICE INTERVIEWS OF PATIENTS

Legal and ethical considerations when law enforcement officials interview hospital patients.

JAMA PATIENT PAGE

For your patients: Information about the metabolic syndrome.

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...